Gain Therapeutics
GANX
GANX
24 hedge funds and large institutions have $5.05M invested in Gain Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4.37% less ownership
Funds ownership: 11.93% → 7.57% (-4.4%)
Holders
24
Holding in Top 10
–
Calls
$54K
Puts
$29K
Top Buyers
| 1 | +$98.7K | |
| 2 | +$63.7K | |
| 3 | +$59.1K | |
| 4 |
Millennium Management
New York
|
+$41.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$37.4K |
Top Sellers
| 1 | -$100K | |
| 2 | -$36.2K | |
| 3 | -$32.7K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$31.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$28K |